BEAM250117P25000
- 1.65
- 0.000.00%
Beam Therapeutics Newsroom
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $42
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $37 to $75
Beam Therapeutics: Strong Pipeline and Strategic Global Expansion Justify Buy Rating
Beam Therapeutics To Present At J.P. Morgan Healthcare Conference; Webcast At 4:30 PM ET
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?
Beam Therapeutics Advances Base Editing Portfolio
Beam Therapeutics Expects Cash Runway To Support Operating Plans Into 2027, Now Inclusive Of Commercial Readiness Activities For BEAM-101
Express News | Beam Therapeutics Inc - Over 40 Adult Sickle Cell Patients Enrolled in Beacon Trial
Express News | Beam Therapeutics Inc - Cash Runway Expected to Support Operations Into 2027
Express News | Beam Therapeutics Inc - Expects to Dose 30 Patients and Present Data by Mid-2025
Express News | Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy
Bernstein Upgrades Beam Therapeutics(BEAM.US) to Buy Rating, Raises Target Price to $37
Beam Upgraded by Bernstein Ahead of AATD Data
Beam Therapeutics Price Target Raised to $37 From $35 at Bernstein
Express News | Beam Therapeutics Inc : Bernstein Raises to Outperform From Market Perform; Raises Target Price to $37 From $35
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?